CYP8B1 (M15-P3B7) Antibody sc-101387 from Santa Cruz Biotechnology, Inc.

Product Specs
ItemCYP8B1 (M15-P3B7) Antibody
CompanySanta Cruz Biotechnology, Inc.
Price $316.00Supplier Page View Company Product Page
Catalog Numbersc-101387
Antibody TypePrimary Antibodies
NCBI Gene AliasesCYP12, CP8B
Quantity200 µg/ml
CloneM15-P3B7
ApplicationsWB, IP, ELISA
Reactivitymouse, rat, human
Conjugate/TagUnconjugated
Hostmouse
FormatPurified
ClonalityMonoclonal
NCBI Full Gene Namecytochrome P450, family 8, subfamily b, polypeptide 1, cytochrome P450 family 8 subfamily B member 1
TargetCYP8B1
IsotypeIgG1

Add to Compare List

Santa Cruz Biotechnology, Inc.

10410 Finnell Street

Dallas, Texas 75220

United States

Phone: 1-800-457-3801
831-457-3801

Company Profile

Website: http://www.scbt.com/

(1) Hepatic protein kinase Cbeta antagonizing p38MAPK to activate ERK1/2 to dysregulate biliary lipid composition upon lithogenic stressAmerican Journal of Physiology-Gastrointestinal and Liver PhysiologyDecember 1, 2025Yaoling Shu, Amit Rai, Gina M. Sizemore, Michael Ostrowski, Wei Huang, Kamal D. Mehtaanti-JNK MAPK (Cell Signaling, #9252), anti-CYP7A1 (Santa Cruz, #sc-518007), anti-CYP8b1 (Santa Cruz, #sc-101387), anti-CYP27A1 (Santa Cruz, #390974), anti-β-Actin (Santa Cruz, #sc-81514), anti-PPARα (Abcam, #ab8934),

(2) Targeting hepatic ceruloplasmin mitigates nonalcoholic steatohepatitis by modulating bile acid metabolismJournal of molecular cell biologyApril 4, 2024Jiang Q, Wang N, Lu S, Xiong J, Yuan Y, Liu J, Chen S.antibody, 1:1000 (Santa Cruz, sc-518007); mouse polyclonal anti-Cyp8b1 antibody, 1:1000 (Santa Cruz, sc-101387); rabbit polyclonal anti-Cyp7b1 antibody, 1:1000 (Abclonal, A17872); rabbit monoclonal anti-Cyp27a1

(3) Restraint stress promotes nonalcoholic steatohepatitis by regulating the farnesoid X receptor/NLRP3 signaling pathwayActa Biochimica et Biophysica SinicaNovember 24, 2023Fan Yang, Xi-Ting Lv, Xiao-Li Lin, Ruo-Hong Wang, Shu-Mei Wang, Guo-En WangSanta Cruz), cholesterol 7α-hydroxylase (CYP7A1, SC-518007; Santa Cruz), sterol 12α-hydroxylase (CYP8B1, SC-101387; Santa Cruz), β-actin (SC-47778; Santa Cruz), Gasdermin D (GSDMD, AF4012; Affinity Biosciences, Cincinnati,

(4) Circadian PER1 controls daily fat absorption with the regulation of PER1-PKA on phosphorylation of bile acid synthetaseJournal of lipid researchJune 1, 2023Ge W, Sun Q, Yang Y, Ding Z, Liu J, Zhang J.Cat# sc-518007, 1:500; anti-PER1, Sigma-Aldrich, Cat# AB2201, 1:200; anti-CYP8B1, Santa Cruz, Cat# sc-101387,1:500; anti-CYP27A1, Santa Cruz, Cat# sc-390974,1:500; anti-HNF-4α, Santa Cruz, Cat# sc-101059,1:500;

(5) Alisol B 23-acetate adjusts bile acid metabolisim via hepatic FXR-BSEP signaling activation to alleviate atherosclerosisPhytomedicine : international journal of phytotherapy and phytopharmacologyJuly 1, 2022Fu Y, Feng H, Ding X, Meng QH, Zhang SR, Li J, Chao Y, Ji TT, Bi YH, Zhang WW, et al.

(6) Inulin activates FXR-FGF15 signaling and further increases bile acids excretion in non-alcoholic fatty liver disease miceBiochemical and biophysical research communicationsApril 16, 2022Wang R, Ren Y, Bao T, Wang T, Li Y, Liu Y, Zhang X, Yang S, Wang H.

(7) Kaempferol acts on bile acid signaling and gut microbiota to attenuate the tumor burden in ApcMin/+ miceEuropean journal of pharmacologyMarch 5, 2022Li X, Khan I, Huang G, Lu Y, Wang L, Liu Y, Lu L, Hsiao WLW, Liu Z.

(8) Disordered farnesoid X receptor signaling is associated with liver carcinogenesis in Abcb11-deficient miceThe Journal of pathologyDecember 1, 2021Wang L, Luo Q, Zeng S, Lou Y, Li X, Hu M, Lu L, Liu Z.

(9) Chemical profile of Swertia mussotii Franch and its potential targets against liver fibrosis revealed by cross-platform metabolomicsJournal of ethnopharmacologyJune 28, 2021Zhang Y, Zhou Q, Ding X, Ma J, Tan G.

(10) Reabsorption of bile acids regulated by FXR-OATP1A2 is the main factor for the formation of cholesterol gallstoneAmerican journal of physiology. Gastrointestinal and liver physiologySeptember 1, 2020Cai J, Wang Z, Chen G, Li D, Liu J, Hu H, Qin J.

(11) F-actin dynamics regulates mammalian organ growth and cell fate maintenanceJournal of hepatologyJuly 1, 2019Pocaterra A, Santinon G, Romani P, Brian I, Dimitracopoulos A, Ghisleni A, Carnicer-Lombarte A, Forcato M, Braghetta P, Montagner M, et al.

(12) Protective effects of yangonin from an edible botanical Kava against lithocholic acid-induced cholestasis and hepatotoxicityEuropean journal of pharmacologyApril 5, 2018Kong Y, Gao X, Wang C, Ning C, Liu K, Liu Z, Sun H, Ma X, Sun P, Meng Q.

(13) Oleanolic acid alters bile acid metabolism and produces cholestatic liver injury in miceToxicology and applied pharmacologyNovember 1, 2013Liu J, Lu YF, Zhang Y, Wu KC, Fan F, Klaassen CD.proteins of interest. The primary antibodies used in this study include Nrf2 (sc-30915) and Cyp8b1 (sc-101387) were from Santa Cruz Biotechnology (Santa Cruz, CA); Nqo1 (Ab2346), Cyp7a1 (Ab79847), and β-actin (Ab8227)

(14) Decreased hepatotoxic bile acid composition and altered synthesis in progressive human nonalcoholic fatty liver diseaseToxicology and applied pharmacologyApril 15, 2013Lake AD, Novak P, Shipkova P, Aranibar N, Robertson D, Reily MD, Lu Z, Lehman-McKeeman LD, Cherrington NJ.were acquired from Abcam Inc. (Cambridge, MA) and Santa Cruz Biotechnology (Santa Cruz, CA). CYP8B1 (sc-101387) was used in 5% nonfat dry milk at a concentration of 1:7,000 with 1:100,000 secondary antibody (sc-2005).

Be the First to Write a Review!

CYP8B1 (M15-P3B7) Antibody

CYP8B1 (M15-P3B7) Antibody from Santa Cruz Biotechnology, Inc.

Description

Santa Cruz Biotechnology, Inc.

Citations (14)

Reviews

CYP8B1 (M15-P3B7) Antibody from Santa Cruz Biotechnology, Inc.

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map